5,517 reports of this reaction
4.2% of all EXENATIDE reports
#5 most reported adverse reaction
BLOOD GLUCOSE DECREASED is the #5 most commonly reported adverse reaction for EXENATIDE, manufactured by AstraZeneca Pharmaceuticals LP. There are 5,517 FDA adverse event reports linking EXENATIDE to BLOOD GLUCOSE DECREASED. This represents approximately 4.2% of all 130,422 adverse event reports for this drug.
Patients taking EXENATIDE who experience blood glucose decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD GLUCOSE DECREASED is moderately reported among EXENATIDE users, representing a notable but not dominant share of adverse events.
In addition to blood glucose decreased, the following adverse reactions have been reported for EXENATIDE:
The following drugs have also been linked to blood glucose decreased in FDA adverse event reports:
BLOOD GLUCOSE DECREASED has been reported as an adverse event in 5,517 FDA reports for EXENATIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD GLUCOSE DECREASED accounts for approximately 4.2% of all adverse event reports for EXENATIDE, making it a notable side effect.
If you experience blood glucose decreased while taking EXENATIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.